Although not all PD-1- and PD-L1-targeted PET tracers have been evaluated in NSCLC tumor models or patients, the significant progress in clinical outcomes achieved by anti-PD-1/PD-L1 treatments in advanced NSCLC patients will undoubtedly promote the applications of these tracers in NSCLC patients. This evidence concerns the gene CD274 and neoplasm.